CoChat
Sign Up
Cited by 98Diabetes and associated disordersDiabetes Management and ResearchT-cell and B-cell Immunology

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Early Development and Spreading of Autoantibodies to Epitopes of IA-2 and Their Association with Progression to Type 1 Diabetes

Open access
Naserke, Heike E, Ziegler, Anette-G, Lampasona, Vito, Bonifacio, Ezio·1998·The Journal of Immunology
DOI 10.4049/jimmunol.161.12.6963
Open this paper in CoChat — free accountOpen PDF

Abstract

Autoimmunity precedes clinical type 1 diabetes, and indicators of maturing autoimmune responses may be useful markers for disease prediction. To study this, epitope maturation of autoantibodies to the related protein tyrosine phosphatase (PTP)-like autoantigens IA-2 and IA-2β was examined in sequential samples from birth in a cohort of 21 offspring developing multiple islet autoantibodies and a similar cohort of 48 relatives of patients with type 1 diabetes recruited at an older age. Initial reactivity in offspring was heterogeneous against the IA-2 juxtamembrane region (10/21) and PTP domains (13/21), and both specificity and extent of initial IA-2/IA-2β autoantibodies were associated with HLA class II genotype. Intra-IA-2 epitope spreading and/or intermolecular spreading to IA-2β epitopes were observed in seven offspring. In contrast, in older relatives, IA-2/IA-2β Ab reactivity was stable and spreading rare. Development of diabetes in children was associated with the presence of Abs to the IA-2 juxtamembrane region (risk by age 5 yr, 52% vs 0% in those with PTP domain Abs only; p < 0.02), and 5 of 26 relatives who developed diabetes had IA-2 Abs only against the juxtamembrane region. The findings show that autoantibody reactivity to IA-2/IA-2β is dynamic in the young, show that the juxtamembrane region of IA-2 is an early IA-2 autoantibody target, and suggest that these Abs are a risk factor for development of type 1 diabetes in infancy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.161.12.6963

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both PTPA and IA-2βA arise later in the humoral response before type 1 diabetes and are associated with rapid progression.

    “Both PTPA and IA‐2βA arise later in the humoral response [ 14 ] before type 1 diabetes and are associated with rapid progression [ 5 ].”

    From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [14]

    The Appearance of IA-2/IA-2β reactivity section reports PTP-domain antibodies in the first detected sample and says their appearance was independent of juxtamembrane antibodies; it does not establish that both types consistently arise later. More decisively, the IA-2/IA-2β Abs and progression to disease section says none of the PTP-domain reactivities was associated with increased diabetes risk in the children studied. It instead associates progression with juxtamembrane antibodies. Page numbers are unavailable in our copy. (LLM, conf=0.88)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 24

  1. 1986, N. Engl. J. Med., 1360
  2. 1990, Lancet, 147
  3. 1994, Diabetes, 1304
  4. 1996, Diabetes, 926
  5. 1998, Diabetes, 592
  6. 1998, J. Clin. Invest., 327
  7. 1998, J. Immunol., 2648
  8. 1998, Diabetes, 733
  9. 1997, J. Exp. Med., 2039
  10. 1996, Diabetes, 967
  11. 1996, Proc. Natl. Acad. Sci. USA, 2307
  12. 1996, Diabetes Nutrition Metab., 183
  13. 1996, J. Immunol., 2707
  14. 1997, Diabetologia, 1327
  15. 1995, J. Clin. Invest., 1506
  16. 1995, J. Immunol., 5419
  17. 1992, HLA 1991, 397
  18. 1988, Am. J. Hum. Genet., 799
  19. 1991, Diabetes, 1146
  20. 1995, J. Clin. Invest., 1505
  21. 1996, Diabetologia, 1223
  22. 1993, J. Exp. Med., 1459
  23. 1995, J. Exp. Med., 1957
  24. 1995, Immunol. Rev., 269

Cited by

Sorted by citations

Related

Metadata

Authors
Naserke, H. E., Ziegler, A.-G., Lampasona, V., & Bonifacio, E.
Affiliations
  • München Klinik Schwabing (DE)
  • München Klinik Bogenhausen (DE)
  • IRCCS Ospedale San Raffaele (IT)
ORCID
Venue
The Journal of Immunology
Publisher
Oxford University Press (OUP)
Published
1998-12
Volume
161
Issue
12
Pages
6963-6969
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
DOI
10.4049/jimmunol.161.12.6963
OpenAlex
W2140103652
Cited by
98
References
25
Citations by year
2022: 2 · 2021: 5 · 2020: 1 · 2019: 3 · 2017: 3 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 1 · 2012: 5
FWCI
3.62
Type
journal article
Language
en
Open access
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Site cant be reached (submittedVersion)
Funders
European Commission
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
type 1 diabetes, IA-2 autoantibodies, juxtamembrane region, disease progression, islet autoantibodies, diabetes risk prediction, autoimmunity
MeSH terms
Adult, Epitopes, Autoantibodies, Autoantigens, Autoimmune Diseases, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family Health, Germany, HLA-D Antigens, Humans, Infant, Islets of Langerhans, Membrane Proteins, Prediabetic State, Prospective Studies, Cohort Studies, Protein Tyrosine Phosphatases, Age of Onset, Disease Progression, Genetic Predisposition to Disease, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Receptor-Like Protein Tyrosine Phosphatases, Class 8

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review